Statistics show that the hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years.
Recently, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. According to this study, this receptor type makes cancer cells resistant to therapy and more aggressive
The findings, reported in the Jan. 1 issue of Cancer Research, could lead to a way to track disease progression, as well as new targets to fight prostate cancer.
Read more about
prostate cancer and hormone deprivation therapy
Study found why prostate cancer patients fail hormone deprivation therapy
Linear Mode
